Events

SHERIDAN, WYOMING - December 19, 2025 - MYTHIC, an overseas high-tech enterprise focused on anti-drone technologies, is expanding its profile as a low-altitude security provider by combining drone detection, intelligent identification, precise tracking, and efficient suppression into integrated defense systems designed for high-value, high-risk environments.

From point solutions to "intelligent airspace security barriers"
MYTHIC frames its core proposition as end-to-end protection against unauthorized UAV activity-built to perform in complex operational settings where disruption is not an option. The company says its solutions are deployed in airports, ports, petrochemical bases, hospitals, schools, luxury hotels, shopping malls, key public safety protection sites, and government office areas, reflecting buyer demand for layered protection that can be tuned to site constraints.

SHERIDAN, WYOMING - December 18, 2025 - Motor Presse Stuttgart is kicking off a year-long anniversary cycle for its flagship automotive media brand auto motor und sport, marking 80 years of publishing with a premium-format XXL issue and a 2026 editorial program designed to deepen reach across print and digital channels.

An anniversary issue designed as a premium brand statement
Motor Presse Stuttgart is launching the jubilee year with an oversized special edition of auto motor und sport featuring a refined additional cover, larger format, and an expanded 232-page scope. The move signals a deliberate positioning strategy: in a fragmented media environment, special-interest publishers are increasingly using premium "event issues" to reinforce brand authority, extend dwell time, and create high-impact inventory for partners.

SHERIDAN, WYOMING - December 18, 2025 - Citroën is using the 2026 Brussels Motor Show as a strategic showcase for its renewed electric portfolio and brand positioning, placing compact EV innovation, comfort-led SUVs and electric motorsport on the radar of European dealers, fleet buyers and mobility partners.

Brussels stand becomes a live lab for Citroën's electrification strategy

At the show, which opens to the public on 9 January 2026, Citroën is building a stand that mirrors its current transformation: colourful, modern and highly focused on accessible, electrified mobility. Alongside the world premiere of the ELO concept, visitors will see the new C5 Aircross as the brand's flagship SUV, the Ami in its new Dark Side edition, and a Formula E single-seater that signals Citroën's next era in electric motorsport.

For B2B stakeholders, the line-up illustrates how Citroën is repositioning its range around:

SHERIDAN, WYOMING - December 18, 2025 - Citroën has appointed Aline Germain as the brand's new marketing lead, effective January 1, 2026, as the automaker continues to sharpen its global positioning across electric, hybrid, and mainstream mobility segments within the Stellantis portfolio.

Leadership change signals renewed focus on brand equity and go-to-market execution
Citroën said Germain will become responsible for Marketing Citroën from 1 january 2026, replacing Federico Goyret, who has been appointed to a position to be announced later. The company said Germain will report to Citroën Brand CEO Xavier Chardon, placing the role at the center of strategy-to-market coordination as Citroën competes for attention in a crowded European and global volume market.

SHERIDAN, WYOMING - December 18, 2025 - A new B2B-focused nautical event, the Napoli Boat Show (NBS), will debut from March 18-22, 2026 at Marina di Stabia in Castellammare di Stabia, positioning itself as a "Boutique Boat Show" built around a simple commercial premise: every boat on display is ready to sail, and sea trials are the norm rather than the exception.

A "Ready-to-Sea" exhibition model built for sales conversations
Unlike traditional dockside showcases, NBS is designed to reverse exhibition logic by putting on-water testing at the center of the buying process. The show's proposition is that there is a material difference between viewing a vessel moored at the quay and experiencing it underway-especially in a setting that allows shipowners and professional buyers to evaluate handling, comfort, and performance in real conditions.

SHERIDAN, WYOMING - December 16, 2025 - Advita Ortho has been recognized with an Innovation award in the 2025 Medical Device Network Excellence Awards for its Newton® Balancing Technology, highlighting the growing clinical and commercial demand for more data-driven, reproducible approaches to soft-tissue management in total knee replacement surgery.

Award recognition spotlights soft-tissue balancing as a key outcomes lever
While implant design and alignment remain central to knee arthroplasty performance, soft-tissue balancing is increasingly viewed as a differentiator in patient satisfaction and functional outcomes. Advita Ortho is positioning Newton as a method to bring greater consistency to what has often been a highly surgeon-dependent step-an area the company notes has historically contributed to dissatisfaction in a meaningful share of procedures.

SHERIDAN, WYOMING - December 15, 2025 - HoldCo Asset Management says Comerica shareholders should vote against the proposed merger with Fifth Third at a special meeting scheduled for January 6, 2026, arguing the transaction undervalues Comerica and that rejecting the deal could improve shareholder outcomes with limited downside.

Activist investor challenges deal process and governance safeguards
HoldCo Asset Management, a Florida-based investment firm managing approximately $2.6 billion in regulatory assets under management, said it holds beneficial ownership of approximately 1.6% of Comerica's outstanding common stock and released a presentation titled "Why We Recommend Voting AGAINST The Proposed Merger and Our Litigation Update." The firm's case centers on how the transaction was negotiated and whether the board's process delivered maximum value for shareholders.

SHERIDAN, WYOMING - December 15, 2025 - TuHURA Biosciences (NASDAQ: HURA) has provided a corporate update following a recent $15.6 million equity financing, detailing near-term milestones across its Phase 3 IFx-2.0 program in Merkel cell carcinoma, its VISTA-inhibiting antibody TBS-2025 in AML, and its Delta Opioid Receptor (DOR)-focused conjugate platform aimed at overcoming resistance to cancer immunotherapy.

SHERIDAN, WYOMING - December 15, 2025 - TuHURA Biosciences, Inc. (NASDAQ:HURA) announced that Kintara's REM-001 clinical trial in ten metastatic cutaneous breast cancer patients met its primary endpoint demonstrating safety, a contractual milestone that is expected to trigger distribution of TuHURA common stock to eligible contingent value right (CVR) holders.

SHERIDAN, WYOMING - December 15, 2025 - Dubai Airshow 2025 opened at Dubai World Central with the Middle East debut of two of China's homegrown C919 aircraft, signaling a higher-profile push by Chinese aerospace players to showcase commercial, unmanned, and next-generation aviation technologies to global buyers.

C919 debut puts China's narrowbody on a new international stage
At the 19th edition of the Dubai Airshow, the appearance of the C919 marked its first showing in the Middle East, with a flight demonstration at the venue. The aircraft's presence matters beyond the air display: for airlines, lessors, MRO providers, and airport stakeholders, international showcases help shape early market perception around supply-chain maturity, support ecosystems, and longer-term export ambitions.

SHERIDAN, WYOMING - December 15, 2025 - ARIDGE has introduced new details on its next-generation A868 flying car concept and confirmed fresh progress at its flying car manufacturing plant, as the company positions two flight systems to serve different segments of China's emerging low-altitude mobility market.

Two flight systems target distinct low-altitude travel needs
ARIDGE framed the low-altitude economy as the next major growth frontier following new energy vehicles, and outlined a dual-product strategy built around different operating missions. The company is developing:

SHERIDAN, WYOMING - December 15, 2025 - XPENG AEROHT has completed a public manned flight of its modular flying car, the "Land Aircraft Carrier," in Dubai and signed purchase agreements totaling 600 flying cars across the Middle East, as the company accelerates overseas expansion and rebrands as ARIDGE.

Dubai manned flight pairs technology validation with commercial traction
The October 12 milestone combined a fully manned demonstration flight with what the company described as record-breaking regional demand, lifting total global orders to over 7,000. The event was witnessed by regional dignitaries, members of the local Chinese community, and more than 100 media outlets, signaling both regulatory interest and market visibility as the "low-altitude economy" shifts from concept showcases to procurement discussions.

SHERIDAN, WYOMING - December 15, 2025 - XPENG AEROHT has secured a manned aircraft special flight permit from the UAE's General Civil Aviation Authority (GCAA) for its modular flying car "Land Aircraft Carrier" in Ras Al Khaimah, enabling manned flight tests across the country and marking a notable step in the overseas commercialization of China's low-altitude eVTOL technology.

Aviation permission becomes a market-entry signal for advanced air mobility
The permit, granted in Ras Al Khaimah, is positioned as the first such authorization obtained by a Chinese flying car company overseas. For B2B stakeholders-from mobility operators to public-sector agencies-regulatory access is often the gating factor that turns "future mobility" narratives into measurable pilots, procurement conversations, and infrastructure planning.

SHERIDAN, WYOMING - December 15, 2025 - XPENG AEROHT, the flying car affiliate of Chinese EV maker XPENG, has begun trial production at what it describes as the world's first intelligent factory for mass-produced flying cars-an operational milestone as next-generation mobility moves from prototypes to industrial output.

Trial production signals a commercialization inflection point
The company started trial production on November 3, 2025, positioning the facility as a bridge between engineering validation and repeatable manufacturing. For the broader eVTOL and "low-altitude mobility" ecosystem, factory readiness matters because it shifts the discussion from flight demonstrations to supply chains, quality systems, and scalable assembly-areas that typically determine whether new vehicle categories can reach customers on schedule.

SHERIDAN, WYOMING - December 15, 2025 - Shanghai is sharpening its push to become a leading center for merger-and-acquisition activity, as the 2025 Mergers and Acquisitions Finance Conference spotlighted stronger regional deal momentum and unveiled a new market index intended to track China's evolving M&A environment.

Policy momentum behind listed-company restructuring
The conference took place as Shanghai marks one year since releasing a three-year action plan aimed at supporting M&A among listed firms. In practical terms, the message to corporate leaders and capital providers is clear: policy alignment and financial-market infrastructure are being positioned to support more transactions that improve efficiency, accelerate industrial upgrading, and strengthen competitiveness in key sectors.

SHERIDAN, WYOMING - December 11, 2025 - The FDA's first use of its new Commissioner's National Priority Voucher (CNPV) has gone not to a cutting-edge biologic, but to a decades-old extended-release antibiotic, Augmentin XR-sending a clear signal that domestic manufacturing and supply resilience are now front-and-center regulatory priorities for the U.S. pharmaceutical industry.

A New Fast-Track Tool Aimed at Supply Chain Security

Launched in June, the CNPV program promises to compress review timelines from the usual 10-12 months to as little as 1-2 months for drugs that align with U.S. "national priorities," such as strengthening domestic production or addressing systemic shortages. The first approval under this framework went to USAntibiotics' Augmentin XR after the FDA completed its review in "just two months," focusing heavily on quality, manufacturing and facility assessments rather than new clinical data.

SHERIDAN, WYOMING - December 11, 2025 - A new convergence of obesity dealmaking, regulatory uncertainty at the U.S. Food and Drug Administration (FDA) and fresh neurology data out of the Clinical Trials on Alzheimer's Disease (CTAD) conference is forcing biopharma executives to recalibrate their 2026 playbooks across R&D, partnering and risk management.

Obesity Dealflow Enters a More Competitive, High-Stakes Phase

Pfizer continues to double down on cardiometabolic disease, following its $10 billion acquisition of obesity startup Metsera with an exclusive collaboration to license YaoPharma's oral GLP-1 receptor agonist YP05002. Together with other emerging oral and peptide GLP-1s, this next wave of assets is pushing obesity beyond a single-product, single-modality market and into a diversified, highly competitive landscape.

SHERIDAN, WYOMING - December 11, 2025 - Saol Therapeutics is turning an FDA rejection into a potential regulatory test case, as the biotech prepares to argue that its pyruvate dehydrogenase complex deficiency (PDCD) drug SL1009 is the ideal "poster child" for the agency's new Rare Disease Evidence Principles (RDEP) framework at a Type A meeting on December 18.

Saol Recasts a Complete Response Letter as a Strategic Opening

On September 8, Saol disclosed that the FDA had issued a complete response letter (CRL) for SL1009, an oral formulation of sodium dichloroacetate for children with PDCD, a genetic disorder affecting fewer than 1,000 people in the U.S. The CRL, according to CEO Dave Penake, "suggested that we would need to do an additional adequate and well controlled clinical trial," and that "and that's not feasible to be done by our company and in this patient population."

SHERIDAN, WYOMING - December 11, 2025 - Terns Pharmaceuticals is rapidly emerging as a serious contender in chronic myeloid leukemia (CML), after early clinical data for its allosteric BCR/ABL1 inhibitor TERN-701 more than doubled response rates seen with Novartis' approved STAMP inhibitor Scemblix in comparable settings and sent the biotech's share price sharply higher.

Best-in-Disease Early Efficacy Raises the Bar in CML

At the American Society of Hematology (ASH) annual meeting, Terns reported Phase I data from the CARDINAL trial in previously treated CML patients, with 38 participants evaluable for efficacy. TERN-701 achieved a major molecular response (MMR) rate of 75% at week 24, with 64% of patients reaching MMR overall in the dataset presented. The investigational agent also supported simple once-daily dosing without a food effect, improving convenience relative to many existing tyrosine kinase inhibitor (TKI) regimens.

SHERIDAN, WYOMING - December 11, 2025 - Mercedes-Benz is expanding its sustainability playbook with "Tomorrow XX", a cross-portfolio technology program designed to decarbonize vehicle components, scale circular materials and turn end-of-life cars into a strategic raw-materials source. For OEMs, suppliers and material innovators, the initiative signals how one of the world's leading premium automotive brands plans to industrialize low-carbon, circular design across its global lineup.

Holistic sustainability roadmap across the Mercedes-Benz portfolio

Tomorrow XX extends the holistic, multi-disciplinary approach first showcased in the VISION EQXX and CONCEPT AMG GT XX to the entire product portfolio, across all drivetrains. From the earliest design stages through to end-of-life, every component and material is being scrutinized for CO₂ impact, resource intensity and recyclability.